Haemonetics (NYSE:HAE) Price Target Raised to $92.00 at Citigroup

Haemonetics (NYSE:HAE) had its price objective increased by Citigroup from $79.00 to $92.00 in a report issued on Friday morning,Benzinga reports. They currently have a neutral rating on the medical instruments supplier’s stock.

Several other research firms have also recently issued reports on HAE. Barrington Research set a $95.00 price objective on Haemonetics in a report on Friday. Mizuho increased their price target on shares of Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $72.00 to $80.00 in a research report on Friday, May 22nd. Raymond James Financial reissued an “outperform” rating and issued a $105.00 target price on shares of Haemonetics in a research report on Friday. Finally, Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.89.

Haemonetics Stock Performance

Shares of HAE stock opened at $87.50 on Friday. The business has a fifty day moving average of $76.98 and a 200 day moving average of $66.52. The company has a debt-to-equity ratio of 1.40, a current ratio of 3.08 and a quick ratio of 1.87. The firm has a market capitalization of $3.98 billion, a price-to-earnings ratio of 42.89, a price-to-earnings-growth ratio of 1.71 and a beta of 0.52. Haemonetics has a 1 year low of $47.31 and a 1 year high of $88.58.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%.The business had revenue of $339.38 million during the quarter, compared to analyst estimates of $327.86 million. During the same quarter last year, the business posted $1.10 EPS. The company’s revenue was up 5.5% on a year-over-year basis. As a group, research analysts expect that Haemonetics will post 5.21 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. North Peak Capital Management LLC boosted its holdings in shares of Haemonetics by 204.4% in the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock valued at $88,405,000 after acquiring an additional 740,626 shares in the last quarter. Aurora Investment Counsel purchased a new stake in Haemonetics during the first quarter worth $1,217,000. London Co. of Virginia grew its stake in Haemonetics by 33.9% in the 1st quarter. London Co. of Virginia now owns 352,807 shares of the medical instruments supplier’s stock valued at $19,884,000 after acquiring an additional 89,242 shares during the last quarter. Strs Ohio acquired a new stake in shares of Haemonetics in the fourth quarter valued at approximately $986,000. Finally, Dimensional Fund Advisors LP increased its position in Haemonetics by 21.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock worth $74,731,000 after buying an additional 233,119 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported fiscal Q1 2027 earnings of $1.14 per share, exceeding the $1.07–$1.08 consensus range. Revenue rose 5.5% year over year to $339.4 million, also comfortably ahead of expectations near $327.9 million. The earnings and sales beats indicate continued operating momentum. Haemonetics Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2027 outlook and now expects reported revenue growth of approximately 5% to 8%. The improved forecast, following a strong first quarter, supports the view that demand and execution are better than previously anticipated. Haemonetics Raises Fiscal 2027 Revenue Guidance
• Positive Sentiment: BTIG Research raised its Haemonetics price target from $84 to $96 and maintained a “buy” rating, implying additional upside based on the company’s earnings performance and outlook. BTIG Raises Haemonetics Price Target
• Neutral Sentiment: Citigroup lifted its price target from $79 to $92, while retaining a “neutral” rating. The higher target reflects improved estimates but suggests limited conviction at the current valuation. Citigroup Analyst Update
• Neutral Sentiment: JPMorgan raised its target from $62 to $86 but maintained a “neutral” rating. The revised target remains slightly below the recent trading level, signaling that valuation may constrain further gains despite the improved outlook. JPMorgan Analyst Update

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.